Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 8, 2014, Pages 3128-3133

  Hoffman, Gregory R ^a   Rahal, Rami ^a,d   Buxton, Frank ^a   Xiang, Kay ^a   McAllister, Gregory ^a   Frias, Elizabeth ^a   Bagdasarian, Linda ^b   Huber, Janina ^a   Lindeman, Alicia ^a   Chen, Dongshu ^a   Romero, Rodrigo ^a   Ramadan, Nadire ^a   Phadke, Tanushree ^a   Haas, Kristy ^a   Jaskelioff, Mariela ^a   Wilson, Boris G ^c   Meyer, Matthew J ^a   Saenz Vash, Veronica ^a   Zhai, Huili ^a   Myer, Vic E ^a   Porter, Jeffery A ^a   Keen, Nicholas ^a   McLaughlin, Margaret E ^b   Mickanin, Craig ^a   Roberts, Charles W M ^c   Stegmeier, Frank ^a   Jagani, Zainab ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Blueprint Medicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVE SITE; EPIGENETICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION;

BLOTTING, WESTERN; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DNA HELICASES; EPIGENESIS, GENETIC; GENE KNOCKDOWN TECHNIQUES; GENE LIBRARY; HISTONES; HUMANS; IMMUNOPRECIPITATION; MULTIPROTEIN COMPLEXES; NEOPLASMS; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84896898658     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316793111     Document Type: Article

References (36)

1. You JS, Jones PA (2012) Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22(1):9-20.
2. Kadoch C, et al. (2013) Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45(6):592-601.
3. Shain AH, Pollack JR (2013) The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8(1):e55119.
4. Wilson BG, Roberts CW (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11(7):481-492.
5. Dykhuizen EC, et al. (2013) BAF complexes facilitate decatenation of DNA by topoisomerase IIα. Nature 497(7451):624-627.
6. Versteege I, et al. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689):203-206. (Pubitemid 28325977)
7. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH (2000) Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97(25):13796-13800.
8. Roberts CW, Leroux MM, Fleming MD, Orkin SH (2002) Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2(5):415-425. (Pubitemid 41039107)
9. Wiegand KC, et al. (2011) Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 224(3):328-333.
10. Wiegand KC, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532-1543.
11. Varela I, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331):539-542.
12. Imielinski M, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107-1120.
13. Matsubara D, et al. (2013) Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci 104(2):266-273.
14. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE (2003) Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: Correlation with poor prognosis. Cancer Res 63(3):560-566. (Pubitemid 36158131)
15. Medina PP, et al. (2008) Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29(5):617-622. (Pubitemid 351614585)
16. Wong AK, et al. (2000) BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 60(21):6171-6177.
17. Becker TM, et al. (2009) The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol Cancer 8:4.
18. Parsons DW, et al. (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331(6016):435-439.
19. Hendricks KB, Shanahan F, Lees E (2004) Role for BRG1 in cell cycle control and tumor suppression. Mol Cell Biol 24(1):362-376. (Pubitemid 38010061)
20. Bultman SJ, et al. (2008) Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27(4):460-468.
21. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
22. Sigoillot FD, King RW (2011) Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 6(1):47-60.
23. König R, et al. (2007) A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 4(10):847-849. (Pubitemid 350055583)
24. Hartigan JA, Wong MA (1979) A K-means clustering algorithm. Appl Stat 28:100-108.
25. Shao DD, et al. (2013) ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res 23(4):665-678.
26. Wang W, et al. (1996) Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15(19):5370-5382. (Pubitemid 26336219)
27. Bultman S, et al. (2000) A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 6(6):1287-1295. (Pubitemid 32045922)
28. Reyes JC, et al. (1998) Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 17(23):6979-6991. (Pubitemid 28550292)
29. Kadam S, Emerson BM (2003) Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 11(2):377-389. (Pubitemid 36293832)
30. Zhao K, et al. (1998) Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell 95(5): 625-636. (Pubitemid 28544124)
31. Narita M, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113(6):703-716. (Pubitemid 36724935)
32. Iorns E, Lord CJ, Turner N, Ashworth A (2007) Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6(7):556-568. (Pubitemid 47019444)
33. Kessler JD, et al. (2012) A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 335(6066):348-353.
34. Bassik MC, et al. (2013) A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152(4):909-922.
35. Wang X, et al. (2009) Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res 69(20):8094-8101.
36. Oike T, et al. (July 19, 2013) A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 73(17):5508-5518.